Lipodystrophy (where the body is unable to produce fat)
This should be done unit by unit if the basal insulin to be replaced by glargine 300U/mL was previously administered as a daily dose
Fasting insulin levels, HOMA-IR (a measure of insulin resistance), high-sensitivity C-reactive protein (an inflammation marker), liver enzymes (indicators of fatty liver disease), and advanced lipid panels all provide evidence of metabolic dysfunction that weight alone cannot capture
Redness and erythema The most common presentation
Drug interactions are clinically relevant and represent one of the most important pre-enrollment conversations to have with a healthcare provider: GLP-1 agonists slow gastric emptying, which can affect the absorption timing and peak concentration of oral medications taken within the same window - a pharmacokinetic effect that's particularly important for drugs with narrow therapeutic windows like levothyroxine, warfarin, or certain oral contraceptives
Arrived quickly and well packaged
